Corvus Pharmaceuticals (CRVS) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Kura Oncology (KURA) over the past year, gaining 45.1% versus a gain of 3.4%. Over five years, CRVS leads with a +106.3% price change compared with -41.2% for KURA. Kura Oncology is the larger company by market cap ($943.0 million vs $885.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | KURA |
|---|---|---|
| Share price | $10.52 | $10.60 |
| Market cap | $884.95M | $942.98M |
| 1-day change | +3.04% | +0.76% |
| YTD return | +36.62% | +2.02% |
| 1-year return | +45.10% | +3.41% |
| 5-year return | +106.26% | -41.18% |
| EPS (TTM) | $-0.62 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.95 | $13.90 |
| 52-week low | $6.39 | $7.36 |
| Distance from 52-week high | -60.96% | -23.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +215.02% | +200.47% |
| Average volume | 982.52K | 1.78M |
| Shares outstanding | 84.12M | 88.96M |
| Employees | 37 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed KURA by 41.7 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
CRVS vs KURA FAQ
Which is bigger, Corvus Pharmaceuticals or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $942.98M compared with $884.95M for Corvus Pharmaceuticals (CRVS).
Which stock has performed better over the past year, CRVS or KURA?
CRVS returned +45.10% over the past 12 months, compared with +3.41% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.